MedTrace Logo

Improved Assessment of Response in Metastatic Renal Cell Carcinoma Using Spectral-CT

NCT03616951 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2020-04-24

No results posted yet for this study

Summary

The incidence of renal cancer in Denmark is approximately 900 new cases per year. Untreated, the 5-year survival rate for metastatic renal cancer (mRCC) is 2%. Development of angiogenesis inhibitors (AI) and check-point immunotherapy (CPI) has improved survival.

Treatment efficacy is evaluated by CT scans, using RESIST 1.1 (Response Evaluation Criteria in Solid Tumors). However, progressin in patients with mRCC treated with AI or CPI is difficult to characterize at the right time, using the RECIST 1.1. Therefore approximately 50 % of the patients are 'lost' to further treatment at the time of progression and die.

The investigators aim to evaluate if functional imaging parameters using spectral CT-techniques can detect treatment failure earlier, or more accurate, than routine CT. This could help us develop a new set of response evaluation criteria for functional imaging, giving a more precise assessment of treatment effect in patients with mRCC treated with AI and CPI.

Conditions

  • Renal Neoplasm With Metastasis
  • Response Evaluation Criteria in Solid Tumors

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Frede Donskov, MD, DMSc · Department of oncology, Aarhus Universety Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2023-01-01
Completion
2024-01-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03616951 on ClinicalTrials.gov